Silver Book Fact

SAS patient hospitalization costs

Symptomatic aortic stenosis (SAS) patients who do not undergo treatment cost Medicare as much as $1.3 billion each year due to rehospitalization, prolonged stays, admissions to skilled nursing facilities, and use of hospice care.

Clark M, Arnold S, Duhay F, et al. Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis. Circulation: Cardiovascular Quality and Outcomes. 2012; 5(5). http://circoutcomes.ahajournals.org/content/5/5/697

Reference

Title
Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis.
Publication
Circulation: Cardiovascular Quality and Outcomes
Publication Date
2012
Authors
Clark M, Arnold S, Duhay F, et al
Volume & Issue
Volume 5, Issue 5
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Survival rates for SAS patients without treatment
     
  • 2016 prevalence of Americans 65+ who had AVD
    In 2016, an estimated 5.2 million U.S. adults ages 65+ had aortic valve disease (AVD).   Note: Alliance for Aging Research generated statistic, based on 2005 percentage prevalence estimates by Bach et al. 2007  
  • Aortic stenosis often undertreated
     
  • SAS patient hospitalization costs
    Symptomatic aortic stenosis (SAS) patients who do not undergo treatment cost Medicare as much as $1.3 billion each year due to rehospitalization, prolonged stays, admissions to skilled nursing facilities, and…  
  • Lifespan of Medicare patients with sSAS who do not undergo treatment
    Medicare patients with severe symptomatic aortic stenosis (sSAS) who do not undergo treatment have an average lifespan of 1.8 years.